These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26709241)

  • 1. Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial.
    Forrester DL; Knox AJ; Smyth AR; Barr HL; Simms R; Pacey SJ; Pavord ID; Honeybourne D; Dewar J; Clayton A; Fogarty AW
    Pediatr Pulmonol; 2016 Mar; 51(3):253-7. PubMed ID: 26709241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc Supplementation for One Year Among Children with Cystic Fibrosis Does Not Decrease Pulmonary Infection.
    Sharma G; Lodha R; Shastri S; Saini S; Kapil A; Singla M; Mukherjee A; Jat KR; Kabra M; Kabra SK
    Respir Care; 2016 Jan; 61(1):78-84. PubMed ID: 26443019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
    Connett GJ; Pike KC; Legg JP; Cathie K; Dewar A; Foote K; Harris A; Faust SN
    Ther Adv Respir Dis; 2015 Dec; 9(6):272-80. PubMed ID: 26341118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic therapy in cystic fibrosis. Evaluation of efficacy.
    Levy J
    Chest; 1988 Aug; 94(2 Suppl):150S-156S. PubMed ID: 3135160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
    Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.
    Stockmann C; Hillyard B; Ampofo K; Spigarelli MG; Sherwin CM
    Expert Rev Respir Med; 2015 Feb; 9(1):13-22. PubMed ID: 25417708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Tai AS; Sherrard LJ; Kidd TJ; Ramsay KA; Buckley C; Syrmis M; Grimwood K; Bell SC; Whiley DM
    BMC Pulm Med; 2017 Nov; 17(1):138. PubMed ID: 29096618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.
    Geller DE; Flume PA; Staab D; Fischer R; Loutit JS; Conrad DJ;
    Am J Respir Crit Care Med; 2011 Jun; 183(11):1510-6. PubMed ID: 21471106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
    Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
    Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection.
    Bisgaard H; Pedersen SS; Nielsen KG; Skov M; Laursen EM; Kronborg G; Reimert CM; Høiby N; Koch C
    Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1190-6. PubMed ID: 9351621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.
    Serisier DJ; Martin ML; McGuckin MA; Lourie R; Chen AC; Brain B; Biga S; Schlebusch S; Dash P; Bowler SD
    JAMA; 2013 Mar; 309(12):1260-7. PubMed ID: 23532242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.
    Høiby N; Koch C
    Thorax; 1990 Nov; 45(11):881-4. PubMed ID: 2256020
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
    Moss RB; Mayer-Hamblett N; Wagener J; Daines C; Hale K; Ahrens R; Gibson RL; Anderson P; Retsch-Bogart G; Nasr SZ; Noth I; Waltz D; Zeitlin P; Ramsey B; Starko K
    Pediatr Pulmonol; 2005 Mar; 39(3):209-18. PubMed ID: 15573395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
    Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
    Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis.
    Hyatt AC; Chipps BE; Kumor KM; Mellits ED; Lietman PS; Rosenstein BJ
    J Pediatr; 1981 Aug; 99(2):307-14. PubMed ID: 7019407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
    Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
    BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.